ReviewNeurochemical research2014
Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries.
Review in Neurochemical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Histone Deacetylase 2 in Alzheimer's Disease: A Comprehensive Molecular Blueprint for Therapeutic Targeting.Molecular neurobiology · 2025Review
- Sodium Valproate Mitigates Hippocampal Structural and Functional Alterations Following Middle Cerebral Artery Occlusion in a Rat Model.Basic and clinical neuroscience · 2025Article
- Prediction Trough Concentrations of Valproic Acid Among Chinese Adult Patients with Epilepsy Using Machine Learning Techniques.Pharmaceutical research · 2025Article
- Anxiolytic and sedative effects of sodium valproate with different experimental paradigms in male and female rats.Neuropsychopharmacology reports · 2024Article
- Review
- Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024Article
- Valproate reduces retinal ganglion cell apoptosis in rats after optic nerve crush.Neural regeneration research · 2023Article
- Use of anti-seizure medications in different types of autoimmune encephalitis: A narrative review.Frontiers in neurology · 2023Review
- Article
- Use of TLC-Densitometric Method for Determination of Valproic Acid in Capsules.Molecules (Basel, Switzerland) · 2022Article
- New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis.Frontiers in pharmacology · 2022Review
- Inflammatory signaling mechanisms in bipolar disorder.Journal of biomedical science · 2021Review
- α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.ACS medicinal chemistry letters · 2020Article
- Effect of valproic acid on oxidative stress parameters of glutamate-induced excitotoxicity in SH-SY5Y cells.Experimental and therapeutic medicine · 2020Article
- Harnessing the HDAC-histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering.International journal of oral science · 2019Review
- Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences.Current neuropharmacology · 2019Review
- Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3.Journal of neuroinflammation · 2018Article
- Transcriptomic changes following valproic acid treatment promote neurogenesis and minimize secondary brain injury.The journal of trauma and acute care surgery · 2018Article
- Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.Neuroscience and biobehavioral reviews · 2018Review
- Valproic Acid Attenuates Traumatic Brain Injury-Induced InflammationFrontiers in molecular neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute central nervous system (CNS) injuries, including stroke, traumatic brain injury (TBI), and spinal cord injury (SCI), are common causes of human disabilities and deaths, but the pathophysiology of these diseases is not fully elucidated and, thus, effective pharmacotherapies are still lacking. Valproic acid (VPA), an inhibitor of histone deacetylation, is mainly used to treat epilepsy and bipolar disorder with few complications. Recently, the neuroprotective effects of VPA have been demonstrated in several models of acute CNS injuries, such as stroke, TBI, and SCI. VPA protects the brain from injury progression via anti-inflammatory, anti-apoptotic, and neurotrophic effects. In this review, we focus on the emerging neuroprotective properties of VPA and explore the underlying mechanisms. In particular, we discuss several potential related factors in VPA research and present the opportunity to administer VPA as a novel neuropective agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.